Your browser doesn't support javascript.
Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study.
Mercado-Reyes, Marcela; Malagón-Rojas, Jeadran; Rodríguez-Barraquer, Isabel; Zapata-Bedoya, Silvana; Wiesner, Magdalena; Cucunubá, Zulma; Toloza-Pérez, Yesith Guillermo; Hernández-Ortiz, Juan P; Acosta-Reyes, Jorge; Parra-Barrera, Eliana; Ibáñez-Beltrán, Edgar; Quinche, Gianni G; Muñoz-Galindo, Lyda; Rubio, Vivian; Galindo-Borda, Marisol; Osorio-Velázquez, Erickson G; Bermúdez-Forero, Andrea; Pinto-Chacón, Nelson; Puerto-Castro, Gloria; Franco-Muñoz, Carlos; Estupiñan, María Isabel; Villar, Luis Ángel; Gore-Saravia, Nancy; Miranda-Montoya, María Consuelo; Castellanos, Jaime; Valle, Edna Margarita; Navarro-Lechuga, Edgar; Oviedo, Juan Daniel; Ospina-Martínez, Martha.
  • Mercado-Reyes M; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Malagón-Rojas J; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Rodríguez-Barraquer I; University of California, San Francisco, CA, USA.
  • Zapata-Bedoya S; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Wiesner M; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Cucunubá Z; Imperial College London, London, UK.
  • Toloza-Pérez YG; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Hernández-Ortiz JP; Universidad Nacional de Colombia, Medellin, Antioquia, Colombia.
  • Acosta-Reyes J; School of Medicine, Universidad del Norte de Barranquilla, Barranquilla, Colombia.
  • Parra-Barrera E; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Ibáñez-Beltrán E; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Quinche GG; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Muñoz-Galindo L; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Rubio V; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Galindo-Borda M; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Osorio-Velázquez EG; Departamento Administrativo Nacional de Estadística - DANE, Bogotá, Colombia.
  • Bermúdez-Forero A; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Pinto-Chacón N; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Puerto-Castro G; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Franco-Muñoz C; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
  • Estupiñan MI; Centro de Atención y Diagnóstico de Enfermedades Infecciosas - CDI, Bucaramanga, Colombia.
  • Villar LÁ; Centro de Atención y Diagnóstico de Enfermedades Infecciosas - CDI, Bucaramanga, Colombia.
  • Gore-Saravia N; Centro Internacional de Entrenamiento e Investigaciones Medicas - CIDEIM, Cali, Colombia.
  • Miranda-Montoya MC; Centro Internacional de Entrenamiento e Investigaciones Medicas - CIDEIM, Cali, Colombia.
  • Castellanos J; Universidad El Bosque, Bogotá, Colombia.
  • Valle EM; Departamento Administrativo Nacional de Estadística - DANE, Bogotá, Colombia.
  • Navarro-Lechuga E; School of Medicine, Universidad del Norte de Barranquilla, Barranquilla, Colombia.
  • Oviedo JD; Departamento Administrativo Nacional de Estadística - DANE, Bogotá, Colombia.
  • Ospina-Martínez M; Instituto Nacional de Salud, Avenida Calle 26 51 -20, Bogotá, Colombia.
Lancet Reg Health Am ; 9: 100195, 2022 May.
Article in English | MEDLINE | ID: covidwho-1665247
ABSTRACT

BACKGROUND:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to cause very high morbidity and mortality throughout Latin American countries. However, few population-based seroprevalence surveys have been conducted to quantify attack rates and characterize drivers of transmission.

METHODS:

We conducted a population-based cross-sectional study to assess the seroprevalence of antibodies against SARS-CoV-2 in ten cities in Colombia between September and December 2020. The study involved multi-stage cluster sampling at each city. Participants provided a serum sample and answered a demographic and risk factor questionnaire. Prior infection by SARS-CoV-2 was ascertained using the "SARS-CoV-2 Total (COV2T) Advia Centaur - Siemens" chemiluminescence assay.

FINDINGS:

A total of 17863 participants from 7320 households participated in the study. Seroprevalence varied substantially between cities, ranging from 26% (95%CI 23-29 %) in Medellín to 68% (95%CI 62-74 %) in Guapi. There were no differences in seroprevalence by sex, but seropositivity was higher in certain ethnic groups. There was substantial heterogeneity in seroprevalence within cities, driven to a large extent by a strong association between socioeconomic stratum and seropositivity.

INTERPRETATION:

Colombia has been one of the Latin American countries most affected by the COVID-19 pandemic. This study documented very high attack rates in several Colombian cities by the end of 2020 and identified key drivers of heterogeneities including ethnicity and socioeconomic stratum. Few studies of seroprevalence of SARS-CoV-2 have been conducted in Latin America, and therefore this study contributes to the fundamental understanding of the pandemic in the region.

FUNDING:

The study was sponsored by, Ministerio de Ciencia y Tecnología e Innovación -CT361/2020, Ministerio de Salud y Protección Social, Fundación Universitaria del Norte, Imperial College of London, Universidad Nacional de Colombia (Sede Medellín), Universidad de Córdoba, California University, Unidad Nacional de Gestión del Riesgo, Centro de Atención y Diagnóstico de Enfermedades Infecciosas -CDI-, Centro Internacional de Entrenamiento e Investigaciones Médicas -CIDEIM-, Departamento Administrativo Nacional de Estadística - DANE, Fondo Nacional de Turismo -FONTUR-, Secretarías de Salud Departamentales, Distritales y Municipales and Instituto Nacional de Salud.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Country/Region as subject: South America / Colombia Language: English Journal: Lancet Reg Health Am Year: 2022 Document Type: Article Affiliation country: J.lana.2022.100195

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Country/Region as subject: South America / Colombia Language: English Journal: Lancet Reg Health Am Year: 2022 Document Type: Article Affiliation country: J.lana.2022.100195